更新于：2024-05-01
Trofosfamide
氯乙环磷酰胺
更新于：2024-05-01
概要
基本信息
结构
分子式C9H18Cl3N2O2P |
InChIKeyUMKFEPPTGMDVMI-UHFFFAOYSA-N |
CAS号22089-22-1 |
关联
5
项与 氯乙环磷酰胺 相关的临床试验A Prospective Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial of Temsirolimus in Combination With Pioglitazone, Etoricoxib and Metronomic Low-dose Trofosfamide Versus Dacarbazine (DTIC) in Patients With Advanced Melanoma
A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults
Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents
100 项与 氯乙环磷酰胺 相关的临床结果
登录后查看更多信息
100 项与 氯乙环磷酰胺 相关的转化医学
登录后查看更多信息
100 项与 氯乙环磷酰胺 相关的专利（医药）
登录后查看更多信息
130
项与 氯乙环磷酰胺 相关的文献（医药）2024-01-23Zhonghua zhong liu za zhi [Chinese journal of oncology]
[Progress in the treatment of soft tissue sarcoma in the 2023 annual meeting of the American Society of Clinical Oncology].
Article
作者: J L Zhao ; W F Liu
Soft tissue sarcoma (STS) is a group of rare malignant tumors originating from mesenchymal tissue, with a high degree of malignancy and a wide range of pathological subtypes. The prognosis varies among different subtypes, and treatment increasingly relies on selecting appropriate treatment methods for different subtypes. Surgical treatment is still the main treatment method at present, and the development of immune and targeted therapy also brings new hope for the treatment of soft tissue sarcoma. Immune checkpoint inhibitors, oncolytic viruses and T cell therapy have shown well safety and efficacy in clinical trials. Targeted drugs such as trabectedin and lenvatinib have changed the treatment pattern of soft tissue sarcoma. Currently, chemotherapy based on doxorubicin and ifosfamide is still the first line treatment for patients with advanced soft tissue sarcoma who have distant metastasis. However, the adverse reactions of doxorubicin limit its application in elderly patients, and trofosfamide has shown good efficacy and safety as an alternative in clinical trials. The efficacy of postoperative radiotherapy has been confirmed, which can reduce the local recurrence rate after surgical resection of soft tissue sarcoma. In summary, multimodal comprehensive treatment has become the main strategy for the treatment of soft tissue sarcoma. The combination of different treatment methods can generate synergistic effects and help patients obtain more clinical benefits, such as the combination of doxorubicin and immune checkpoint inhibitors, and the combination of antiangiogenic drugs and chemotherapy drugs. At the 2023 annual meeting of the American Society of Clinical Oncology (ASCO), oncologists from all over the world reported many researches related to the treatment of soft tissue sarcoma. This article aims to review the new progress in the treatment of soft tissue sarcoma in the 2023 annual meeting of ASCO.
2023-10-09Pediatric blood & cancer
Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR.
Article
作者: Amadeus T Heinz ; Anton Schönstein ; Martin Ebinger ; Jörg Fuchs ; Beate Timmermann ; Guido Seitz ; Christian Vokuhl ; Marc Münter ; Kristian W Pajtler ; Sabine Stegmaier ; Thekla von Kalle ; Christian P Kratz ; Gustaf Ljungman ; Hanna Juntti ; Thomas Klingebiel ; Ewa Koscielniak ; Monika Sparber-Sauer ; Cooperative Weichteilsarkom Studiengruppe
BACKGROUND:
Outcome of primary metastatic rhabdomyosarcoma (RMS) is poor. Certain risk factors as fusion status, Oberlin score, and local treatment of primary tumor are known to influence prognosis.
PROCEDURE:
Patients with metastatic RMS were treated according to Cooperative Weichteilsarkom Studiengruppe (CWS) guidance with chemotherapy (CHT), radiotherapy (RT) excluding total lung irradiation (TLI), complete resection of the primary tumor, and metastasectomy if possible. Kaplan-Meier estimators and Cox proportional hazard models were used to examine event-free survival (EFS) and overall survival (OS) involving also landmark analyses.
RESULTS:
In the European Soft Tissue Sarcoma Registry SoTiSaR (2009-2018), 211 patients were analyzed. Many patients had fusion-positive alveolar RMS (n = 83; 39%). Median age was 9.4 years [0.1-19.7 years]. Treatment primarily consisted of CHT with CEVAIE (carboplatin, epirubicine, vincristine, actinomycin-D, ifosfamide, etoposide: 86%, other regimens: 14%), RT (71%), resection of primary tumor (37%), metastasectomy (19%), and lymph node sampling/dissection (21%). Maintenance treatment (MT) (oral trofosfamide, idarubicin, etoposide) was added in 74% of patients. Oberlin factors, fusion status, and MT were predictive for EFS and OS. MT with O-TIE was not improving outcome when adjusting for the immortal time bias. Local treatment of the primary tumor and radical irradiation (except TLI) improved EFS, not OS, when adjusting for the Oberlin score. Patients with fusion-negative alveolar RMS (n = 9) had an excellent outcome with a 5-year EFS and OS of 100%, compared to patients with embryonal RMS (49%/62%), PAX7- (22%/47%) and PAX3/FOXO1-positive ARMS (10/13%), respectively (p < .001).
CONCLUSIONS:
Prognosis of metastatic RMS primarily depends on fusion status and Oberlin score. Fusion status needs to be considered in future trials to optimize treatment outcome. The role of radical irradiation needs further investigation.
2023-08-07Cancers
Maintenance Chemotherapy for Patients with Rhabdomyosarcoma.
Review
作者: Gianni Bisogno ; Veronique Minard-Colin ; Meriel Jenney ; Andrea Ferrari ; Julia Chisholm ; Daniela Di Carlo ; Lisa Lyngsie Hjalgrim ; Daniel Orbach ; Johannes Hendrikus Maria Merks ; Michela Casanova
Maintenance chemotherapy (MC) defines the administration of prolonged relatively low-intensity chemotherapy with the aim of "maintaining" tumor complete remission. This paper aims to report an update of the RMS2005 trial, which demonstrated better survival for patients with high-risk localized rhabdomyosarcoma (RMS) when MC with vinorelbine and low-dose cyclophosphamide was added to standard chemotherapy, and to discuss the published experience on MC in RMS. In the RMS2005 study, the outcome for patients receiving MC vs. those who stopped the treatment remains superior, with a 5-year disease-free survival of 78.1% vs. 70.1% (p = 0.056) and overall survival of 85.0% vs. 72.4% (p = 0.008), respectively. We found seven papers describing MC in RMS, but only one randomized trial that did not demonstrate any advantage when MC with eight courses of trofosfamide/idarubicine alternating with trofosfamide/etoposide has been employed in high-risk RMS. The use of MC showed better results in comparison to high-dose chemotherapy in non-randomized studies, including metastatic patients, and demonstrated feasibility and tolerability in relapsed RMS. Many aspects of MC in RMS need to be investigated, including the best drug combination and the optimal duration. The ongoing EpSSG trial will try to answer some of these questions.
100 项与 氯乙环磷酰胺 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 肿瘤 | 批准上市 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 转移性软组织肉瘤 一线 | - | (蓋簾繭齋積蓋廠選衊淵) = 膚壓膚窪襯願觸簾醖醖 衊醖繭憲積蓋淵鬱醖鏇 (鹽構繭餘廠醖衊襯積簾, 1.6 ~ 20.9) 更多 | 积极 | 2018-06-01 | ||
(蓋簾繭齋積蓋廠選衊淵) = 簾淵鑰鹹構鑰網鑰夢觸 衊醖繭憲積蓋淵鬱醖鏇 (鹽構繭餘廠醖衊襯積簾, 2.2 ~ 14.9%) 更多 | |||||||
N/A | - | (遞構願遞積簾顧遞顧獵) = 獵築鹽糧網網壓艱膚壓 網餘鏇簾選繭遞壓鹹衊 (構積顧網獵壓醖夢網選, 9.96 ~ 18.04) 更多 | 积极 | 2013-09-01 | |||
临床3期 | 195 | (築積選齋觸繭蓋夢簾衊) = Toxicity grade 3 (no grade 4) in the M-arm was: hematological in 51 %, febrile infection 5%, sensory neuropathy in 1% pts 艱鑰鑰觸膚鑰衊築獵積 (鬱齋餘範鹹鹹蓋觸簾襯 ) 更多 | 不佳 | 2022-06-02 | |||
N/A | 10 | 願顧網觸選選窪簾齋齋(醖簾夢繭遞遞積鏇襯網) = Acute toxicity was mainly hematologic 網繭遞夢鬱簾顧範範簾 (衊夢淵鹽淵願淵鹽鏇選 ) 更多 | - | 2008-05-20 | |||
临床2期 | 转移性软组织肉瘤 一线 | 120 | (構蓋蓋鑰繭顧壓鑰鹹範) = 齋鹽夢觸選選餘憲衊夢 遞觸顧顧鹹鬱壓觸積獵 (選壓構廠繭範鏇餘夢鹹, 18.0 ~ 39.1) 更多 | 积极 | 2020-01-01 | ||
(構蓋蓋鑰繭顧壓鑰鹹範) = 製範醖糧窪膚餘鑰衊積 遞觸顧顧鹹鬱壓觸積獵 (選壓構廠繭範鏇餘夢鹹, 21.2 ~ 52.8) 更多 | |||||||
N/A | 21 | 願繭繭選鬱憲鏇鬱餘膚(窪網獵襯衊遞糧糧範鏇) = 鹹鑰醖壓淵繭鑰糧襯糧 範鬱窪繭廠願壓襯鑰夢 (醖願夢繭餘觸膚觸積襯, 14.5 ~ 56.2) 更多 | - | 2007-06-20 | |||
N/A | - | (構繭艱觸簾齋獵鏇鏇糧) = 獵衊積選膚鏇襯壓顧壓 積齋遞壓鑰廠鑰衊餘淵 (鹽遞選膚齋淵膚鬱範築 ) | - | 2007-06-20 | |||
憲築襯憲鹽鹽鏇簾壓夢(觸淵壓窪簾遞憲窪繭齋) = 選鏇鑰選選醖衊襯齋糧 壓鏇膚鹽艱顧觸醖觸醖 (鹹鹽襯艱襯淵壓選淵餘 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用